SIT: Efficacy depends on product, not on route of application

Pediatric Allergy and Immunology

Volumn 23, Issue 4, 2012, Pages 401-401

  Bachert, Claus ^a   Walter Canonica, G ^b   Bufe, Albrecht ^c  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF GENOA   (Italy)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; HOUSE DUST ALLERGEN; ORALGEN; UNCLASSIFIED DRUG;

DERMATOPHAGOIDES; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; GRASS POLLEN; HOUSE DUST ALLERGY; HUMAN; LETTER; PATIENT SAFETY; PRIORITY JOURNAL; SUBLINGUAL IMMUNOTHERAPY; THERAPY EFFECT;

ANIMALS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; PYROGLYPHIDAE;

EID: 84861310921     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2012.01285.x     Document Type: Letter

References (4)

1. de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol 2012: 23: 149-57.
2. Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007: 119: 892-8.
3. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009: 123: 167-73.
4. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009: 123: 160-6.